Tagged: NICE guidance

NICE recommends new treatment for people with common heart condition

In final draft guidance, NICE has recommended Apixaban (Eliquis, Bristol-Myers Squibb and Pfizer), in accordance with its licensed indications, for the prevention of stroke and systemic embolism in some people with non-valvular atrial fibrillation. Read the guidance

| In Clinical | Tagged , | Leave a comment

Spot signs of psychosis and schizophrenia early, says NICE

The signs of psychosis and schizophrenia in children and young people need identifying early to make sure they receive the treatment and care they need to live with the condition, says NICE. In the first clinical guideline to focus specifically … Read more → – Spot signs of psychosis and schizophrenia early, says NICE

| In Clinical | Tagged , , | Leave a comment

New NICE guidelines

NICE has recently published guidelines on: Hepatitis B and C – ways to promote and offer testing Ectopic pregnancy and miscarriage Leukaemia (acute myeloid) – decitabine Melanoma (BRAF V600 mutation positive, unresectable metastatic – vemurafenib Melanoma (stage III or IV) … Read more → – New NICE guidelines

| In Clinical, Resources | Tagged | Leave a comment

NICE approves drug for treatment of chronic heart failure

GPs with a specialist interest in heart failure and other healthcare professionals can now use ivabradine (Procoralan) as an option for the treatment of people with chronic heart failure, following latest guidance from NICE. More information and final guidance is … Read more → – NICE approves drug for treatment of chronic heart failure

| In Clinical | Tagged , , , | Leave a comment

Help for the treatment of Crohn’s disease

New guidance from NICE provides GPs and other healthcare professionals with advice on the use of glucocorticosteroids for the remission and management of people with Crohn’s disease. Around 115,000 people currently have the condition in the UK, with between 3000 … Read more → – Help for the treatment of Crohn’s disease

| In Clinical | Tagged , | Leave a comment